Dr. Lenz highlighted precision oncology beyond DNA, emphasizing RNA, methylation, and the tumor microenvironment. Emerging ADCs, CAR T, and engineered antibodies may expand options, especially for MSS disease.

The panel discussed limits of CMS classification, highlighting AI, spatial transcriptomics, and single-cell profiling to improve precision. CAR T shows promise but remains limited in advanced GI cancers.